Yahoo Finance EN

UBS Boosts Bristol-Myers Squibb (BMY) Price Target as Milvexian Data Looms

Mar 10, 2026 &03191010202631; 17:19 UTC finance.yahoo.com Trending 3/5

Read original on finance.yahoo.com ↗

↗

Positive for markets

Sentiment score: +75/100

Moderate impact Short-term (days)

WHAT THIS MEANS

UBS has increased its price target for Bristol-Myers Squibb (BMY) ahead of anticipated Milvexian clinical data release, signaling confidence in the company's pipeline prospects. This positive analyst action reflects optimism regarding the drug candidate's potential market impact and commercial viability.

AI CONFIDENCE

78% High

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↑

BMY

BMYStock

Expected to rise

UBS price target increase reflects positive outlook on Milvexian clinical data and pipeline strength

↑

S&P 500

^GSPCIndex

Expected to rise

Positive pharmaceutical sector sentiment may provide modest support to broader market

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Consider accumulating BMY positions ahead of Milvexian data release, as positive clinical results could drive significant upside. Monitor data announcement timing closely as this represents a near-term catalyst with binary outcome potential.

KEY SIGNALS

Analyst price target upgradeUpcoming clinical data catalystPipeline confidence indicatorMilvexian development milestone

SECTORS INVOLVED

HealthcarePharmaceuticalsBiotechnology

Analysis generated on Mar 11, 2026 at 01:10 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Yahoo Finance. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

UBS Boosts Bristol-Myers Squibb (BMY) Price Target as Milvexian Data Looms

RELATED INTELLIGENCE